JP2013514977A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013514977A5 JP2013514977A5 JP2012544838A JP2012544838A JP2013514977A5 JP 2013514977 A5 JP2013514977 A5 JP 2013514977A5 JP 2012544838 A JP2012544838 A JP 2012544838A JP 2012544838 A JP2012544838 A JP 2012544838A JP 2013514977 A5 JP2013514977 A5 JP 2013514977A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- poly
- polymer
- bound
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 claims 28
- 239000013543 active substance Substances 0.000 claims 22
- 229920000642 polymer Polymers 0.000 claims 11
- 230000002209 hydrophobic effect Effects 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 229920002988 biodegradable polymer Polymers 0.000 claims 4
- 239000004621 biodegradable polymer Substances 0.000 claims 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims 4
- 125000000524 functional group Chemical group 0.000 claims 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 4
- 229960001756 oxaliplatin Drugs 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229920001400 block copolymer Polymers 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 claims 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims 2
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical compound C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 claims 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims 2
- 229960005215 dichloroacetic acid Drugs 0.000 claims 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims 2
- 229960003538 lonidamine Drugs 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- GEWDNTWNSAZUDX-UHFFFAOYSA-N methyl 7-epi-jasmonate Natural products CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 claims 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229940016667 resveratrol Drugs 0.000 claims 2
- 235000021283 resveratrol Nutrition 0.000 claims 2
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- LKFHUFAEFBRVQX-UHFFFAOYSA-N decanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCCCCCCCC(O)=O LKFHUFAEFBRVQX-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003118 drug derivative Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229920001600 hydrophobic polymer Polymers 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 125000001151 peptidyl group Chemical group 0.000 claims 1
- -1 poly (alkylene glycol Chemical compound 0.000 claims 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28718809P | 2009-12-16 | 2009-12-16 | |
| US61/287,188 | 2009-12-16 | ||
| PCT/US2010/060814 WO2011084620A2 (en) | 2009-12-16 | 2010-12-16 | Particles for multiple agent delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013514977A JP2013514977A (ja) | 2013-05-02 |
| JP2013514977A5 true JP2013514977A5 (enExample) | 2014-02-06 |
Family
ID=44306061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544838A Pending JP2013514977A (ja) | 2009-12-16 | 2010-12-16 | 複数の物質の送達のための粒子 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130017265A1 (enExample) |
| EP (1) | EP2512522A4 (enExample) |
| JP (1) | JP2013514977A (enExample) |
| CN (1) | CN102791294A (enExample) |
| EA (1) | EA201290506A1 (enExample) |
| IN (1) | IN2012DN05099A (enExample) |
| WO (1) | WO2011084620A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161734B2 (en) | 2009-07-02 | 2024-12-10 | Sloan-Kettering Institute For Cancer Research | Multimodal silica-based nanoparticles |
| US9625456B2 (en) | 2009-07-02 | 2017-04-18 | Sloan-Kettering Institute For Cancer Research | Fluorescent silica-based nanoparticles |
| CA2792035A1 (en) * | 2010-03-02 | 2011-09-09 | Vindico Nanobio Technology, Inc. | Compositions and methods for treating or preventing immuno-inflammatory disease |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9901616B2 (en) | 2011-08-31 | 2018-02-27 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013096596A1 (en) * | 2011-12-20 | 2013-06-27 | Latham Keith R | Sustained drug release and improved product stability using non-covalent particle coating methods |
| HRP20181671T1 (hr) | 2012-02-09 | 2018-12-14 | Novus International, Inc. | Heteroatom koji sadrži cikličke dimere |
| US10416167B2 (en) | 2012-02-17 | 2019-09-17 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| PL2871973T3 (pl) | 2012-07-12 | 2019-02-28 | Novus International Inc. | Kompozycje matrycy i warstwy do ochrony środków bioaktywnych |
| JP2014051478A (ja) * | 2012-09-10 | 2014-03-20 | Panasonic Corp | 機能性物質、生体活性用薬剤及び機能性物質の生体内への浸透方法、並びに機能性物質放散装置及び空気清浄装置 |
| WO2014059022A1 (en) | 2012-10-09 | 2014-04-17 | The Brigham And Women's Hospital, Inc. | Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use |
| WO2014078470A1 (en) * | 2012-11-14 | 2014-05-22 | Cornell University | Drug delivery compositions and methods targeting p-glycoprotein |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| RU2015132626A (ru) | 2013-03-15 | 2017-04-25 | Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч | Мультимодальные наночастицы на основе диоксида кремния |
| JP2016526011A (ja) * | 2013-04-09 | 2016-09-01 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | 併用療法用ナノ粒子 |
| JP6470740B2 (ja) | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| JP2016523926A (ja) | 2013-07-01 | 2016-08-12 | ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド | 抗癌療法のための細胞ミトコンドリアへの治療剤の正確な送達 |
| EP3024495A4 (en) * | 2013-07-26 | 2017-03-22 | The University Of British Columbia | Method and device for manufacturing polymer particles containing a therapeutic material |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| CA2931638A1 (en) * | 2013-12-12 | 2015-06-18 | University Of Georgia Research Foundation, Inc. | Prodrug for release of cisplatin and cyclooxygenase inhibitor |
| CN113349707A (zh) | 2013-12-31 | 2021-09-07 | 纪念斯隆-凯特琳癌症中心 | 用于荧光源实时多通道成像的系统、方法和设备 |
| WO2015138992A1 (en) | 2014-03-14 | 2015-09-17 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
| EP3129017A4 (en) * | 2014-04-08 | 2017-11-08 | University of Georgia Research Foundation, Inc. | Mitochondria-targeting platinum(iv) prodrug |
| ES2788865T3 (es) | 2014-05-29 | 2020-10-23 | Memorial Sloan Kettering Cancer Center | Conjugados farmacéuticos de nanopartículas |
| CA2962251A1 (en) | 2014-10-03 | 2016-04-07 | Ntercept, Llc | Compositions and methods for inhibiting the biological activity of soluble biomolecules |
| BR112017024328A2 (pt) | 2015-05-29 | 2018-07-24 | Univ Cornell | métodos de tratamento usando nanopartículas ultrapequenas para induzir morte celular de células cancerosas privadas de nutrientes via ferroptose |
| KR20180021805A (ko) * | 2015-06-25 | 2018-03-05 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 약제학적 공-결정 조성물 및 이의 용도 |
| CA2995372C (en) * | 2015-08-13 | 2023-10-24 | Northeastern University | Biomaterials for combined radiotherapy and immunotherapy of cancer |
| CA3001727A1 (en) * | 2015-11-18 | 2017-05-26 | Synergy Pharmaceuticals, Inc. | Compositions and method for the treatment and detection of colon cancer |
| US20200179528A9 (en) * | 2015-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Immune cell-targeted particles |
| EP3445385A4 (en) | 2016-04-18 | 2019-11-20 | The Trustees of Columbia University in the City of New York | THERAPEUTIC GOALS INVOLVED IN THE PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) |
| US11065345B2 (en) * | 2017-01-04 | 2021-07-20 | Nanotics, Llc | Methods for assembling scavenging particles |
| AU2018271781A1 (en) | 2017-05-25 | 2019-12-12 | Cornell University | Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof |
| US10584306B2 (en) | 2017-08-11 | 2020-03-10 | Board Of Regents Of The University Of Oklahoma | Surfactant microemulsions |
| CA3224718A1 (en) * | 2021-06-21 | 2022-12-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions, methods, and devices for sustained release of an agent |
| CN114259573B (zh) * | 2022-01-06 | 2023-06-20 | 中国人民解放军军事科学院军事医学研究院 | 一种含有胆碱酯酶重活化剂的脑靶向脂质体及其制备方法和用途 |
| CN115382476B (zh) * | 2022-07-26 | 2024-10-22 | 华东师范大学 | 一种超小粒径聚合物纳米颗粒的制备方法 |
| WO2025240771A1 (en) * | 2024-05-16 | 2025-11-20 | Curadel Surgical Innovations, Inc. | Small zwitterionic multimeric targeted drugs and methods of use and manufacture thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
| US5565215A (en) * | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| EP1125577B1 (en) * | 1994-04-08 | 2006-02-15 | QLT USA, Inc. | Liquid drug delivery compositions |
| KR0180334B1 (ko) * | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| US20020164374A1 (en) * | 1997-10-29 | 2002-11-07 | John Jackson | Polymeric systems for drug delivery and uses thereof |
| KR19990085365A (ko) * | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6482439B2 (en) * | 1999-12-29 | 2002-11-19 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| ATE449596T1 (de) * | 2000-08-15 | 2009-12-15 | Univ Illinois | Verfahren zur herstellung von mikropartikeln |
| WO2002026241A1 (en) * | 2000-09-26 | 2002-04-04 | Center For Advanced Science And Technology Incubation, Ltd. | Polymeric micelle containing cisplatin enclosed therein and use thereof |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| US7371781B2 (en) * | 2003-09-22 | 2008-05-13 | University Of Utah Research Foundation | Tumor environment-induced ligand-expressing nanocarrier system |
| AU2003272127A1 (en) * | 2003-10-24 | 2005-05-11 | Samyang Corporation | Polymeric composition for drug delivery |
| NZ550964A (en) * | 2004-04-28 | 2011-05-27 | Angiodevice Internat Gmbh | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
| IL180785A (en) * | 2004-07-19 | 2014-03-31 | Celator Pharmaceuticals Inc | Preparations containing particulate structures for the release of active substances |
| IL178645A0 (en) * | 2006-10-16 | 2007-02-11 | Ariel University Res And Dev C | Dendrimeric platform for controlled release of drugs |
| CN101679021B (zh) * | 2007-03-02 | 2014-04-30 | 伊利诺伊大学评议会 | 药物颗粒送递 |
| EP2155253A2 (en) * | 2007-05-09 | 2010-02-24 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
-
2010
- 2010-12-16 IN IN5099DEN2012 patent/IN2012DN05099A/en unknown
- 2010-12-16 CN CN2010800640099A patent/CN102791294A/zh active Pending
- 2010-12-16 WO PCT/US2010/060814 patent/WO2011084620A2/en not_active Ceased
- 2010-12-16 EP EP10842613.1A patent/EP2512522A4/en not_active Withdrawn
- 2010-12-16 JP JP2012544838A patent/JP2013514977A/ja active Pending
- 2010-12-16 US US13/515,668 patent/US20130017265A1/en not_active Abandoned
- 2010-12-16 EA EA201290506A patent/EA201290506A1/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tang et al. | Shell-detachable micelles based on disulfide-linked block copolymer as potential carrier for intracellular drug delivery | |
| Enlow et al. | Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings | |
| Zhu | Flash nanoprecipitation: prediction and enhancement of particle stability via drug structure | |
| Xu et al. | Injectable, NIR/pH-responsive nanocomposite hydrogel as long-acting implant for chemophotothermal synergistic cancer therapy | |
| Zhang et al. | Polymeric micelles: nanocarriers for cancer-targeted drug delivery | |
| Glavas et al. | Achieving micelle control through core crystallinity | |
| Irani et al. | RETRACTED: A novel biocompatible drug delivery system of chitosan/temozolomide nanoparticles loaded PCL-PU nanofibers for sustained delivery of temozolomide | |
| Matai et al. | Chemically cross-linked hybrid nanogels of alginate and PAMAM dendrimers as efficient anticancer drug delivery vehicles | |
| Cu et al. | Controlled surface modification with poly (ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus | |
| Mahmud et al. | Novel self-associating poly (ethylene oxide)-b lock-poly (ε-caprolactone) block copolymers with functional side groups on the polyester block for drug delivery | |
| Thapa et al. | Multilayer-coated liquid crystalline nanoparticles for effective sorafenib delivery to hepatocellular carcinoma | |
| Li et al. | Driving forces for drug loading in drug carriers | |
| Garbuzenko et al. | Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs | |
| Ribeiro et al. | Advances in Hybrid Polymer‐Based Materials for Sustained Drug Release | |
| Joy et al. | Brief outlook on polymeric nanoparticles, micelles, niosomes, hydrogels and liposomes: preparative methods and action | |
| Frasco et al. | Transferrin surface‐modified PLGA nanoparticles‐mediated delivery of a proteasome inhibitor to human pancreatic cancer cells | |
| Luo et al. | Layer-by-layer polyelectrolyte–polyester hybrid microcapsules for encapsulation and delivery of hydrophobic drugs | |
| Guo et al. | Preparation of curcumin-loaded PCL-PEG-PCL triblock copolymeric nanoparticles by a microchannel technology | |
| Mehnath et al. | Co-encapsulation of dual drug loaded in MLNPs: Implication on sustained drug release and effectively inducing apoptosis in oral carcinoma cells | |
| Vučen et al. | Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles | |
| Meng et al. | Tenofovir containing thiolated chitosan core/shell nanofibers: in vitro and in vivo evaluations | |
| Stoicea et al. | Advanced analgesic drug delivery and nanobiotechnology | |
| Singh et al. | Nanoparticle formulations: a sustainable approach to biodegradable and non‐biodegradable products | |
| Wang et al. | Materials, syntheses and biomedical applications of nano-quercetin formulations: a comprehensive literature review | |
| Dinakar et al. | Recent advances of multifunctional PLGA nanocarriers in the management of triple-negative breast cancer |